BN-1001

N/A

Report date: 2025/03/21 11:31:00

Base Information

Drug NameBN-1001
Drug Alias NameBN-1001BN1001
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionVascular endothelial growth factor inhibitors
TargetsVascular endothelial growth factor
Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBionce Biotechnology Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBionce Biotechnology Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaWet age-related macular degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A